Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Abstract

There are as yet no licensed therapeutics for the COVID-19 pandemic. The causal coronavirus (SARS-CoV-2) binds host cells via a trimeric spike whose receptor binding domain (RBD) recognizes angiotensin-converting enzyme 2, initiating conformational changes that drive membrane fusion. We find that the monoclonal antibody CR3022 binds the RBD tightly, neutralizing SARS-CoV-2, and report the crystal structure at 2.4 Å of the Fab/RBD complex. Some crystals are suitable for screening for entry-blocking inhibitors. The highly conserved, structure-stabilizing CR3022 epitope is inaccessible in the prefusion spike, suggesting that CR3022 binding facilitates conversion to the fusion-incompetent post-fusion state. Cryogenic electron microscopy (cryo-EM) analysis confirms that incubation of spike with CR3022 Fab leads to destruction of the prefusion trimer. Presentation of this cryptic epitope in an RBD-based vaccine might advantageously focus immune responses. Binders at this epitope could be useful therapeutically, possibly in synergy with an antibody that blocks receptor attachment.

References 60

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.
    Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R · 2006

    No notice
12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.
    Acaricide, Fungicide and Drug Interactions in Honey Bees (Apis mellifera) · 2013

    No notice
15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.
    Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus · 2012

    Corrected
19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.
    REFMAC 5 for the refinement of macromolecular crystal structures · 2011

    No notice
24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.
    Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants · 2006

    No notice
26. 26.
    Phaser crystallographic software · 2007

    No notice
27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.
    GISAID: Global initiative on sharing all influenza data – from vision to reality · 2017

    No notice
32. 32.
    Antibody therapies for the prevention and treatment of viral infections · 2017

    No notice
33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.
    DIALS : implementation and evaluation of a new integration package · 2018

    No notice
35. 35.
    Three-dimensional Epigenome Statistical Model: Genome-wide Chromatin Looping Prediction · 2018

    No notice
36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.
    Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 · 2018

    No notice
38. 38.
    Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis · 2018

    Corrected
39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 11

• Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses · 2022
  Not checked
• Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines · 2022
  No notice
• The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022
  No notice
• Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
  No notice
• Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study · 2021
  No notice
• Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class · 2021
  Not checked
• The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates · 2021
  No notice
• Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape · 2021
  No notice
• A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 · 2021
  No notice
• Antibodies and Vaccines Target RBD of SARS-CoV-2 · 2021
  No notice
• Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.